NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.94 +0.13 (+0.82 %)
(As of 01/22/2019 06:34 AM ET)
Previous Close$15.81
Today's Range$15.55 - $16.12
52-Week Range$10.75 - $25.96
Volume189,714 shs
Average Volume199,435 shs
Market Capitalization$691.57 million
P/E RatioN/A
Dividend YieldN/A
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, as well as a strategic research collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RCKT



Sales & Book Value

Annual SalesN/A
Book Value$7.02 per share


Net Income$-29,490,000.00


Market Cap$691.57 million

Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) posted its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.03. View Rocket Pharmaceuticals' Earnings History.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Rocket Pharmaceuticals.

What price target have analysts set for RCKT?

5 brokerages have issued twelve-month price targets for Rocket Pharmaceuticals' shares. Their forecasts range from $22.00 to $30.00. On average, they expect Rocket Pharmaceuticals' share price to reach $26.3333 in the next year. This suggests a possible upside of 65.2% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals.

What is the consensus analysts' recommendation for Rocket Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals.

What are Wall Street analysts saying about Rocket Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rocket Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. " (1/9/2019)
  • 2. William Blair analysts commented, "Rocket Pharmaceuticals, Inc. We are initiating coverage of Outperform rating and $32 fair value estimate. Rocket is a multi-platform biotechnology company that is focused on developing irst-in-class gene thera pies for rare dis- eases. The company’s lead candidate, RP-L102, is an ex vivo lentiviral gene therapy being developed for the treatment of Fanconi anemia (FA), with three additional ex vivo lentivirus programs in earlier development for the treatment of leukocyte adhesion deiciency-I (LAD-I), pyruvate kinase deiciency (PKD) , and infantile malignant osteopetrosis (IMO). We also expect the company to disclose its in vivo adeno-associated virus (AAV) gene therapy indication by year end, as the company anticipates having up to four programs in the clinic (likely and data from two (likely FA, LAD-I) in 2019. Plat- form and Longer Follow-Up." (7/10/2018)

Has Rocket Pharmaceuticals been receiving favorable news coverage?

Headlines about RCKT stock have trended very positive on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rocket Pharmaceuticals earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Rocket Pharmaceuticals' key competitors?

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the folowing people:
  • Mr. Gaurav Shah, CEO, Pres & Director (Age 43)
  • Mr. John C. Militello, Principal Financial & Accounting Officer and Controller (Age 45)
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, Chief Operating Officer & Head of Devel. (Age 39)
  • Dr. Claudine Prowse Ph.D., Sr. VP Corp. Devel. & IRO
  • Mr. Jonathan Schwartz, Chief Medical Officer (Age 54)

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Nisa Investment Advisors LLC (0.01%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Kinnari Patel and Naveen Yalamanchi. View Institutional Ownership Trends for Rocket Pharmaceuticals.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Rocket Pharmaceuticals.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $15.94.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $691.57 million. Rocket Pharmaceuticals employs 20 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]

MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel